|
1
|
Shestakova KM, Moskaleva NE, Mesonzhnik NV, Kukharenko AV, Serkov IV, Lyubimov II, Fomina-Ageeva EV, Bezuglov VV, Akimov MG, Appolonova SA. In Vivo Targeted Metabolomic Profiling of Prostanit, a Novel Anti-PAD NO-Donating Alprostadil-Based Drug. Molecules 2020; 25:E5896. [PMID: 33322104 PMCID: PMC7764275 DOI: 10.3390/molecules25245896] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2020] [Revised: 12/08/2020] [Accepted: 12/09/2020] [Indexed: 11/16/2022] Open
Abstract
Prostanit is a novel drug developed for the treatment of peripheral arterial diseases. It consists of a prostaglandin E1 (PGE1) moiety with two nitric oxide (NO) donor fragments, which provide a combined vasodilation effect on smooth muscles and vascular spastic reaction. Prostanit pharmacokinetics, however, remains poorly investigated. Thus, the object of this study was to investigate the pharmacokinetics of Prostanit-related and -affected metabolites in rabbit plasma using the liquid chromatography-mass spectrometry (LC-MS) approach. Besides, NO generation from Prostanit in isolated rat aorta and human smooth muscle cells was studied using the Griess method. In plasma, Prostanit was rapidly metabolized to 1,3-dinitroglycerol (1,3-DNG), PGE1, and 13,14-dihydro-15-keto-PGE1. Simultaneously, the constant growth of amino acid (proline, 4-hydroxyproline, alanine, phenylalanine, etc.), steroid (androsterone and corticosterone), and purine (adenosine, adenosine-5 monophosphate, and guanosine) levels was observed. Glycine, aspartate, cortisol, and testosterone levels were decreased. Ex vivo Prostanit induced both NO synthase-dependent and -independent NO generation. The observed pharmacokinetic properties suggested some novel beneficial activities (i.e., effect prolongation and anti-inflammation). These properties may provide a basis for future research of the effectiveness and safety of Prostanit, as well as for its characterization from a clinical perspective.
Collapse
Affiliation(s)
- Ksenia M. Shestakova
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia; (K.M.S.); (N.E.M.); (N.V.M.); (A.V.K.); (S.A.A.)
| | - Natalia E. Moskaleva
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia; (K.M.S.); (N.E.M.); (N.V.M.); (A.V.K.); (S.A.A.)
| | - Natalia V. Mesonzhnik
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia; (K.M.S.); (N.E.M.); (N.V.M.); (A.V.K.); (S.A.A.)
| | - Alexey V. Kukharenko
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia; (K.M.S.); (N.E.M.); (N.V.M.); (A.V.K.); (S.A.A.)
| | - Igor V. Serkov
- Institute of Physiologically Active Compounds RAS, Severniy pr., 1, 142432 Chernogolovka, Russia;
| | - Igor I. Lyubimov
- Territory of Skolkovo Innovation Center, LLC “Gurus BioPharm”, Bolshoy Boulevard, 42 Building 1, 143026 Moscow, Russia;
| | - Elena V. Fomina-Ageeva
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, St. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (E.V.F.-A.); (V.V.B.)
| | - Vladimir V. Bezuglov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, St. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (E.V.F.-A.); (V.V.B.)
| | - Mikhail G. Akimov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, St. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (E.V.F.-A.); (V.V.B.)
| | - Svetlana A. Appolonova
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia; (K.M.S.); (N.E.M.); (N.V.M.); (A.V.K.); (S.A.A.)
| |
Collapse
|